The Experts below are selected from a list of 15 Experts worldwide ranked by ideXlab platform
Glasson, William J. - One of the best experts on this subject based on the ideXlab platform.
-
A panel of circulating microRNAs detects Uveal melanoma with high precision
'Association for Research in Vision and Ophthalmology (ARVO)', 2019Co-Authors: Stark, Mitchell S., Gray, Elin S., Isaacs Timothy, Chen, Fred K., Millward Michael, Mcevoy Ashleigh, Zaenker Pauline, Ziman Melanie, Soyer H. Peter, Glasson, William J.Abstract:To determine if a circulating microRNA (miRNA) panel could be used to distinguish between Uveal melanoma and Uveal nevi.We report on a multicenter, cross-sectional study conducted between June 2012 and September 2015. The follow-up time was approximately 3 to 5 years. Blood was drawn from participants presenting with a Uveal Nevus ( = 10), localized Uveal melanoma ( = 50), or metastatic Uveal melanoma ( = 5). Levels of 17 miRNAs were measured in blood samples of study participants using a sensitive real-time PCR system.A panel of six miRNAs (miR-16, miR-145, miR-146a, miR-204, miR-211, and miR-363-3p) showed significant differences between participants with Uveal nevi compared with patients with localized and metastatic Uveal melanoma. Importantly, miR-211 was able to accurately distinguish metastatic disease from localized Uveal melanoma ( < 0.0001; area under the curve = 0.96). When the six-miRNA panel was evaluated as a group it had the ability to identify Uveal melanoma when four or more miRNAs (93% sensitivity and 100% specificity) reached or exceeded their cut-point.This miRNA panel, in tandem with clinical findings, may be suited to confirm benign lesions. In addition, due to the panel's high precision in identifying malignancy, it has the potential to augment melanoma detection in subsequent clinical follow-up of lesions with atypical clinical features.Uveal nevi mimic the appearance of Uveal melanoma and their transformation potential cannot be definitively determined without a biopsy. This panel is most relevant at the Nevus stage and in lesions with uncertain malignant potential as a companion diagnostic tool to assist in clinical decision-making
-
A panel of circulating MicroRNAs detects Uveal melanoma with high precision
Edith Cowan University Research Online Perth Western Australia, 2019Co-Authors: Stark, Mitchell S., Gray, Elin S., Isaacs Timothy, Chen, Fred K., Millward Michael, Mcevoy Ashleigh, Zaenker Pauline, Ziman Melanie, Soyer H. Peter, Glasson, William J.Abstract:Purpose: To determine if a circulating microRNA (miRNA) panel could be used to distinguish between Uveal melanoma and Uveal nevi. Methods: We report on a multicenter, cross-sectional study conducted between June 2012 and September 2015. The follow-up time was approximately 3 to 5 years. Blood was drawn from participants presenting with a Uveal Nevus (n = 10), localized Uveal melanoma (n = 50), or metastatic Uveal melanoma (n = 5). Levels of 17 miRNAs were measured in blood samples of study participants using a sensitive real-time PCR system. Results: A panel of six miRNAs (miR-16, miR-145, miR-146a, miR-204, miR-211, and miR-363-3p) showed significant differences between participants with Uveal nevi compared with patients with localized and metastatic Uveal melanoma. Importantly, miR-211 was able to accurately distinguish metastatic disease from localized Uveal melanoma (P \u3c 0.0001; area under the curve = 0.96). When the six-miRNA panel was evaluated as a group it had the ability to identify Uveal melanoma when four or more miRNAs (93% sensitivity and 100% specificity) reached or exceeded their cut-point. Conclusions: This miRNA panel, in tandem with clinical findings, may be suited to confirm benign lesions. In addition, due to the panel’s high precision in identifying malignancy, it has the potential to augment melanoma detection in subsequent clinical follow-up of lesions with atypical clinical features. Translational Relevance: Uveal nevi mimic the appearance of Uveal melanoma and their transformation potential cannot be definitively determined without a biopsy. This panel is most relevant at the Nevus stage and in lesions with uncertain malignant potential as a companion diagnostic tool to assist in clinical decision-making
Stark, Mitchell S. - One of the best experts on this subject based on the ideXlab platform.
-
A panel of circulating microRNAs detects Uveal melanoma with high precision
'Association for Research in Vision and Ophthalmology (ARVO)', 2019Co-Authors: Stark, Mitchell S., Gray, Elin S., Isaacs Timothy, Chen, Fred K., Millward Michael, Mcevoy Ashleigh, Zaenker Pauline, Ziman Melanie, Soyer H. Peter, Glasson, William J.Abstract:To determine if a circulating microRNA (miRNA) panel could be used to distinguish between Uveal melanoma and Uveal nevi.We report on a multicenter, cross-sectional study conducted between June 2012 and September 2015. The follow-up time was approximately 3 to 5 years. Blood was drawn from participants presenting with a Uveal Nevus ( = 10), localized Uveal melanoma ( = 50), or metastatic Uveal melanoma ( = 5). Levels of 17 miRNAs were measured in blood samples of study participants using a sensitive real-time PCR system.A panel of six miRNAs (miR-16, miR-145, miR-146a, miR-204, miR-211, and miR-363-3p) showed significant differences between participants with Uveal nevi compared with patients with localized and metastatic Uveal melanoma. Importantly, miR-211 was able to accurately distinguish metastatic disease from localized Uveal melanoma ( < 0.0001; area under the curve = 0.96). When the six-miRNA panel was evaluated as a group it had the ability to identify Uveal melanoma when four or more miRNAs (93% sensitivity and 100% specificity) reached or exceeded their cut-point.This miRNA panel, in tandem with clinical findings, may be suited to confirm benign lesions. In addition, due to the panel's high precision in identifying malignancy, it has the potential to augment melanoma detection in subsequent clinical follow-up of lesions with atypical clinical features.Uveal nevi mimic the appearance of Uveal melanoma and their transformation potential cannot be definitively determined without a biopsy. This panel is most relevant at the Nevus stage and in lesions with uncertain malignant potential as a companion diagnostic tool to assist in clinical decision-making
-
A panel of circulating MicroRNAs detects Uveal melanoma with high precision
Edith Cowan University Research Online Perth Western Australia, 2019Co-Authors: Stark, Mitchell S., Gray, Elin S., Isaacs Timothy, Chen, Fred K., Millward Michael, Mcevoy Ashleigh, Zaenker Pauline, Ziman Melanie, Soyer H. Peter, Glasson, William J.Abstract:Purpose: To determine if a circulating microRNA (miRNA) panel could be used to distinguish between Uveal melanoma and Uveal nevi. Methods: We report on a multicenter, cross-sectional study conducted between June 2012 and September 2015. The follow-up time was approximately 3 to 5 years. Blood was drawn from participants presenting with a Uveal Nevus (n = 10), localized Uveal melanoma (n = 50), or metastatic Uveal melanoma (n = 5). Levels of 17 miRNAs were measured in blood samples of study participants using a sensitive real-time PCR system. Results: A panel of six miRNAs (miR-16, miR-145, miR-146a, miR-204, miR-211, and miR-363-3p) showed significant differences between participants with Uveal nevi compared with patients with localized and metastatic Uveal melanoma. Importantly, miR-211 was able to accurately distinguish metastatic disease from localized Uveal melanoma (P \u3c 0.0001; area under the curve = 0.96). When the six-miRNA panel was evaluated as a group it had the ability to identify Uveal melanoma when four or more miRNAs (93% sensitivity and 100% specificity) reached or exceeded their cut-point. Conclusions: This miRNA panel, in tandem with clinical findings, may be suited to confirm benign lesions. In addition, due to the panel’s high precision in identifying malignancy, it has the potential to augment melanoma detection in subsequent clinical follow-up of lesions with atypical clinical features. Translational Relevance: Uveal nevi mimic the appearance of Uveal melanoma and their transformation potential cannot be definitively determined without a biopsy. This panel is most relevant at the Nevus stage and in lesions with uncertain malignant potential as a companion diagnostic tool to assist in clinical decision-making
Gray, Elin S. - One of the best experts on this subject based on the ideXlab platform.
-
A panel of circulating microRNAs detects Uveal melanoma with high precision
'Association for Research in Vision and Ophthalmology (ARVO)', 2019Co-Authors: Stark, Mitchell S., Gray, Elin S., Isaacs Timothy, Chen, Fred K., Millward Michael, Mcevoy Ashleigh, Zaenker Pauline, Ziman Melanie, Soyer H. Peter, Glasson, William J.Abstract:To determine if a circulating microRNA (miRNA) panel could be used to distinguish between Uveal melanoma and Uveal nevi.We report on a multicenter, cross-sectional study conducted between June 2012 and September 2015. The follow-up time was approximately 3 to 5 years. Blood was drawn from participants presenting with a Uveal Nevus ( = 10), localized Uveal melanoma ( = 50), or metastatic Uveal melanoma ( = 5). Levels of 17 miRNAs were measured in blood samples of study participants using a sensitive real-time PCR system.A panel of six miRNAs (miR-16, miR-145, miR-146a, miR-204, miR-211, and miR-363-3p) showed significant differences between participants with Uveal nevi compared with patients with localized and metastatic Uveal melanoma. Importantly, miR-211 was able to accurately distinguish metastatic disease from localized Uveal melanoma ( < 0.0001; area under the curve = 0.96). When the six-miRNA panel was evaluated as a group it had the ability to identify Uveal melanoma when four or more miRNAs (93% sensitivity and 100% specificity) reached or exceeded their cut-point.This miRNA panel, in tandem with clinical findings, may be suited to confirm benign lesions. In addition, due to the panel's high precision in identifying malignancy, it has the potential to augment melanoma detection in subsequent clinical follow-up of lesions with atypical clinical features.Uveal nevi mimic the appearance of Uveal melanoma and their transformation potential cannot be definitively determined without a biopsy. This panel is most relevant at the Nevus stage and in lesions with uncertain malignant potential as a companion diagnostic tool to assist in clinical decision-making
-
A panel of circulating MicroRNAs detects Uveal melanoma with high precision
Edith Cowan University Research Online Perth Western Australia, 2019Co-Authors: Stark, Mitchell S., Gray, Elin S., Isaacs Timothy, Chen, Fred K., Millward Michael, Mcevoy Ashleigh, Zaenker Pauline, Ziman Melanie, Soyer H. Peter, Glasson, William J.Abstract:Purpose: To determine if a circulating microRNA (miRNA) panel could be used to distinguish between Uveal melanoma and Uveal nevi. Methods: We report on a multicenter, cross-sectional study conducted between June 2012 and September 2015. The follow-up time was approximately 3 to 5 years. Blood was drawn from participants presenting with a Uveal Nevus (n = 10), localized Uveal melanoma (n = 50), or metastatic Uveal melanoma (n = 5). Levels of 17 miRNAs were measured in blood samples of study participants using a sensitive real-time PCR system. Results: A panel of six miRNAs (miR-16, miR-145, miR-146a, miR-204, miR-211, and miR-363-3p) showed significant differences between participants with Uveal nevi compared with patients with localized and metastatic Uveal melanoma. Importantly, miR-211 was able to accurately distinguish metastatic disease from localized Uveal melanoma (P \u3c 0.0001; area under the curve = 0.96). When the six-miRNA panel was evaluated as a group it had the ability to identify Uveal melanoma when four or more miRNAs (93% sensitivity and 100% specificity) reached or exceeded their cut-point. Conclusions: This miRNA panel, in tandem with clinical findings, may be suited to confirm benign lesions. In addition, due to the panel’s high precision in identifying malignancy, it has the potential to augment melanoma detection in subsequent clinical follow-up of lesions with atypical clinical features. Translational Relevance: Uveal nevi mimic the appearance of Uveal melanoma and their transformation potential cannot be definitively determined without a biopsy. This panel is most relevant at the Nevus stage and in lesions with uncertain malignant potential as a companion diagnostic tool to assist in clinical decision-making
Isaacs Timothy - One of the best experts on this subject based on the ideXlab platform.
-
A panel of circulating microRNAs detects Uveal melanoma with high precision
'Association for Research in Vision and Ophthalmology (ARVO)', 2019Co-Authors: Stark, Mitchell S., Gray, Elin S., Isaacs Timothy, Chen, Fred K., Millward Michael, Mcevoy Ashleigh, Zaenker Pauline, Ziman Melanie, Soyer H. Peter, Glasson, William J.Abstract:To determine if a circulating microRNA (miRNA) panel could be used to distinguish between Uveal melanoma and Uveal nevi.We report on a multicenter, cross-sectional study conducted between June 2012 and September 2015. The follow-up time was approximately 3 to 5 years. Blood was drawn from participants presenting with a Uveal Nevus ( = 10), localized Uveal melanoma ( = 50), or metastatic Uveal melanoma ( = 5). Levels of 17 miRNAs were measured in blood samples of study participants using a sensitive real-time PCR system.A panel of six miRNAs (miR-16, miR-145, miR-146a, miR-204, miR-211, and miR-363-3p) showed significant differences between participants with Uveal nevi compared with patients with localized and metastatic Uveal melanoma. Importantly, miR-211 was able to accurately distinguish metastatic disease from localized Uveal melanoma ( < 0.0001; area under the curve = 0.96). When the six-miRNA panel was evaluated as a group it had the ability to identify Uveal melanoma when four or more miRNAs (93% sensitivity and 100% specificity) reached or exceeded their cut-point.This miRNA panel, in tandem with clinical findings, may be suited to confirm benign lesions. In addition, due to the panel's high precision in identifying malignancy, it has the potential to augment melanoma detection in subsequent clinical follow-up of lesions with atypical clinical features.Uveal nevi mimic the appearance of Uveal melanoma and their transformation potential cannot be definitively determined without a biopsy. This panel is most relevant at the Nevus stage and in lesions with uncertain malignant potential as a companion diagnostic tool to assist in clinical decision-making
-
A panel of circulating MicroRNAs detects Uveal melanoma with high precision
Edith Cowan University Research Online Perth Western Australia, 2019Co-Authors: Stark, Mitchell S., Gray, Elin S., Isaacs Timothy, Chen, Fred K., Millward Michael, Mcevoy Ashleigh, Zaenker Pauline, Ziman Melanie, Soyer H. Peter, Glasson, William J.Abstract:Purpose: To determine if a circulating microRNA (miRNA) panel could be used to distinguish between Uveal melanoma and Uveal nevi. Methods: We report on a multicenter, cross-sectional study conducted between June 2012 and September 2015. The follow-up time was approximately 3 to 5 years. Blood was drawn from participants presenting with a Uveal Nevus (n = 10), localized Uveal melanoma (n = 50), or metastatic Uveal melanoma (n = 5). Levels of 17 miRNAs were measured in blood samples of study participants using a sensitive real-time PCR system. Results: A panel of six miRNAs (miR-16, miR-145, miR-146a, miR-204, miR-211, and miR-363-3p) showed significant differences between participants with Uveal nevi compared with patients with localized and metastatic Uveal melanoma. Importantly, miR-211 was able to accurately distinguish metastatic disease from localized Uveal melanoma (P \u3c 0.0001; area under the curve = 0.96). When the six-miRNA panel was evaluated as a group it had the ability to identify Uveal melanoma when four or more miRNAs (93% sensitivity and 100% specificity) reached or exceeded their cut-point. Conclusions: This miRNA panel, in tandem with clinical findings, may be suited to confirm benign lesions. In addition, due to the panel’s high precision in identifying malignancy, it has the potential to augment melanoma detection in subsequent clinical follow-up of lesions with atypical clinical features. Translational Relevance: Uveal nevi mimic the appearance of Uveal melanoma and their transformation potential cannot be definitively determined without a biopsy. This panel is most relevant at the Nevus stage and in lesions with uncertain malignant potential as a companion diagnostic tool to assist in clinical decision-making
Chen, Fred K. - One of the best experts on this subject based on the ideXlab platform.
-
A panel of circulating microRNAs detects Uveal melanoma with high precision
'Association for Research in Vision and Ophthalmology (ARVO)', 2019Co-Authors: Stark, Mitchell S., Gray, Elin S., Isaacs Timothy, Chen, Fred K., Millward Michael, Mcevoy Ashleigh, Zaenker Pauline, Ziman Melanie, Soyer H. Peter, Glasson, William J.Abstract:To determine if a circulating microRNA (miRNA) panel could be used to distinguish between Uveal melanoma and Uveal nevi.We report on a multicenter, cross-sectional study conducted between June 2012 and September 2015. The follow-up time was approximately 3 to 5 years. Blood was drawn from participants presenting with a Uveal Nevus ( = 10), localized Uveal melanoma ( = 50), or metastatic Uveal melanoma ( = 5). Levels of 17 miRNAs were measured in blood samples of study participants using a sensitive real-time PCR system.A panel of six miRNAs (miR-16, miR-145, miR-146a, miR-204, miR-211, and miR-363-3p) showed significant differences between participants with Uveal nevi compared with patients with localized and metastatic Uveal melanoma. Importantly, miR-211 was able to accurately distinguish metastatic disease from localized Uveal melanoma ( < 0.0001; area under the curve = 0.96). When the six-miRNA panel was evaluated as a group it had the ability to identify Uveal melanoma when four or more miRNAs (93% sensitivity and 100% specificity) reached or exceeded their cut-point.This miRNA panel, in tandem with clinical findings, may be suited to confirm benign lesions. In addition, due to the panel's high precision in identifying malignancy, it has the potential to augment melanoma detection in subsequent clinical follow-up of lesions with atypical clinical features.Uveal nevi mimic the appearance of Uveal melanoma and their transformation potential cannot be definitively determined without a biopsy. This panel is most relevant at the Nevus stage and in lesions with uncertain malignant potential as a companion diagnostic tool to assist in clinical decision-making
-
A panel of circulating MicroRNAs detects Uveal melanoma with high precision
Edith Cowan University Research Online Perth Western Australia, 2019Co-Authors: Stark, Mitchell S., Gray, Elin S., Isaacs Timothy, Chen, Fred K., Millward Michael, Mcevoy Ashleigh, Zaenker Pauline, Ziman Melanie, Soyer H. Peter, Glasson, William J.Abstract:Purpose: To determine if a circulating microRNA (miRNA) panel could be used to distinguish between Uveal melanoma and Uveal nevi. Methods: We report on a multicenter, cross-sectional study conducted between June 2012 and September 2015. The follow-up time was approximately 3 to 5 years. Blood was drawn from participants presenting with a Uveal Nevus (n = 10), localized Uveal melanoma (n = 50), or metastatic Uveal melanoma (n = 5). Levels of 17 miRNAs were measured in blood samples of study participants using a sensitive real-time PCR system. Results: A panel of six miRNAs (miR-16, miR-145, miR-146a, miR-204, miR-211, and miR-363-3p) showed significant differences between participants with Uveal nevi compared with patients with localized and metastatic Uveal melanoma. Importantly, miR-211 was able to accurately distinguish metastatic disease from localized Uveal melanoma (P \u3c 0.0001; area under the curve = 0.96). When the six-miRNA panel was evaluated as a group it had the ability to identify Uveal melanoma when four or more miRNAs (93% sensitivity and 100% specificity) reached or exceeded their cut-point. Conclusions: This miRNA panel, in tandem with clinical findings, may be suited to confirm benign lesions. In addition, due to the panel’s high precision in identifying malignancy, it has the potential to augment melanoma detection in subsequent clinical follow-up of lesions with atypical clinical features. Translational Relevance: Uveal nevi mimic the appearance of Uveal melanoma and their transformation potential cannot be definitively determined without a biopsy. This panel is most relevant at the Nevus stage and in lesions with uncertain malignant potential as a companion diagnostic tool to assist in clinical decision-making
